Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes

doi:10.1111/liv.14385

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24847

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24847

Title:	Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
Authors:	Yen, FS;Yang, YC;Hwu, CM;Wei, JCC;Huang, YH;Hou, MC;Hsu, CC
Keywords:	nonalcoholic fatty liver disease;cirrhosis;hepatic decompensation;hepatic failure;all-cause mortality;liver-related death
Date:	2020
Issue Date:	2022-08-09T08:08:57Z (UTC)
Publisher:	WILEY
ISSN:	1478-3223
Abstract:	Background & Aims Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short term with moderate sample size, no liver-related long-term outcomes could be noted. Methods This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality between TZD users and nonusers. The Kaplan-Meier method was used to compare the cumulative incidence of these main outcomes. Results The incidence rates of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality during follow-up were 0.77 vs 1.95, 1.43 vs 1.75, 0.36 vs 0.70, and 4.89 vs 3.78 per 1000 person-years between TZD users and nonusers. The adjusted hazard ratios of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality were 0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 (95% CI: 0.18-1.17) and 1.18 (95% CI: 0.87-1.61) respectively. Conclusions Our study demonstrated that TZD use could significantly lower the risk of cirrhosis. In clinical settings, TZD use might be able to improve liver-related long-term outcomes.
URI:	http://dx.doi.org/10.1111/liv.14385 https://www.webofscience.com/wos/woscc/full-record/WOS:000512129200001 https://ir.csmu.edu.tw:8080/handle/310902500/24847
Relation:	LIVER INTERNATIONAL ,2020 ,v40 ,issue 5 ,p1089-1097
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	178	View/Open

Loading...